TactiFlex Paroxysmal Atrial Fibrillation IDE Trial

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 355 participants.

Also called NCT04356040

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 355 participants (enrolled count) (from the registry)
Sponsor
  • Abbott Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04356040
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Austria, Canada, Czechia, Germany, Hong Kong SAR China, Italy, Netherlands, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04356040. Non-randomized; no masking; primary purpose treatment. Start 2020-06-29 (actual); primary completion 2022-07-01 (actual). Results posted on 2023-10-31.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
TactiFlex Paroxysmal Atrial Fibrillation IDE Trial
Condition
Paroxysmal Atrial Fibrillation
Intervention (Device)
TactiFlex SE
Intervention (Device)
TactiFlex SE - High Standard Power
Lead sponsor
Abbott Medical Devices (class: industry)

Record details

Record id
cardio:ct-nct04356040
Content hash
a2ef9ba20bed7ee9bf7d08532771fb8642284119cc437eed1936256d3a6eeccd